Share-based Payment Arrangement, Expense in USD of Barinthus Biotherapeutics plc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Barinthus Biotherapeutics plc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q1 2020 to Q3 2025.
  • Barinthus Biotherapeutics plc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was -$415K, a 136% decline year-over-year.
  • Barinthus Biotherapeutics plc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $527K, a 88.9% decline year-over-year.
  • Barinthus Biotherapeutics plc. annual Share-based Payment Arrangement, Expense for 2024 was $4.71M, a 6.85% decline from 2023.
  • Barinthus Biotherapeutics plc. annual Share-based Payment Arrangement, Expense for 2023 was $5.06M, a 48.8% decline from 2022.
  • Barinthus Biotherapeutics plc. annual Share-based Payment Arrangement, Expense for 2022 was $9.88M, a 40.1% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Barinthus Biotherapeutics plc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $527K -$415K -$1.56M -136% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025
Q2 2025 $2.09M -$281K -$1.48M -124% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $3.56M $468K -$1.15M -71% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $4.71M $755K -$31K -3.94% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025
Q3 2024 $4.74M $1.14M +$1.09M +1907% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025
Q2 2024 $3.65M $1.2M -$795K -40% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $4.45M $1.62M -$607K -27.3% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 $5.06M $786K -$1.26M -61.5% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 $6.31M $57K -$1.05M -94.8% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 $7.36M $1.99M -$758K -27.6% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $8.12M $2.22M -$1.76M -44.2% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 $9.88M $2.04M -$1.54M -43% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024
Q3 2022 $11.4M $1.1M -$2.27M -67.3% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $13.7M $2.75M -$5.99M -68.5% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 $19.7M $3.98M +$3.19M +400% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023
Q4 2021 $16.5M $3.58M +$1.38M +62.7% 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023
Q3 2021 $15.1M $3.37M +$3.22M +2091% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $11.9M $8.74M +$8.32M +2005% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 $3.57M $797K -$59K -6.89% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022
Q4 2020 $3.63M $2.2M 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022
Q3 2020 $154K 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 $415K 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 $856K 01 Jan 2020 31 Mar 2020 10-Q 14 Jun 2021

Barinthus Biotherapeutics plc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $4.71M -$346K -6.85% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025
2023 $5.06M -$4.82M -48.8% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025
2022 $9.88M -$6.61M -40.1% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024
2021 $16.5M +$12.9M +355% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023
2020 $3.63M 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.